Suppr超能文献

肉毒毒素治疗手部震颤。

Botulinum Toxin for the Treatment of Hand Tremor.

机构信息

Parkinson's Disease Center and Movement Disorders Clinic, Department of Neurology, Baylor College of Medicine, Houston, TX 77030, USA.

出版信息

Toxins (Basel). 2018 Jul 19;10(7):299. doi: 10.3390/toxins10070299.

Abstract

The aim of this study is to review our longitudinal experience with onabotulinumtoxinA (onaBoNT-A) injections for medically refractory hand tremor. We performed a retrospective review of our database of patients treated with onaBoNT-A for hand tremor evaluated between 2010 and 2018 in at least 2 sessions with follow-up. The majority were injected into the forearm flexors (FF), although treatment was individualized. During the specified period, 91 patients (53 essential tremor, 31 dystonic tremor, 6 Parkinson's disease tremor, and 1 cerebellar outflow tremor) met our inclusion criteria. The mean age (SD) was 64.8 years (12.8), and mean duration of follow-up was 29.6 months (25.1) with mean of 7.7 (6.3) treatment visits. FF were injected in 89 (97.8%) patients, exclusively in 74 (81.3%), and 15 (16.5%) were injected in FF and other muscles. EMG guidance was used in 5 patients (5.5%). On a 0⁻4 "peak effect" rating scale (0 = no effect, 4 = marked improvement in severity and function), 80.2% and 85.7% of patients reported moderate or marked improvement (score 3 or 4) at their first and last follow-up visit, respectively. There was no statistically significant difference in the outcomes between first and last visit: average "peak effect" rating score (3.2 versus 3.4), "global" rating score (3.0 versus 3.2), latency of response (4.5 versus 3.8 days), and total duration of response (12.7 versus 12.8 weeks), except onaBoNT-A dose (65.0 versus 78.6 U/limb, = 0.002). Of 1095 limb injections, there were 134 (12.2%) non-disabling and transient (mean 36 days) adverse events (132 limb weakness, 2 pain). OnaBoNT-A injections are safe and effective in the treatment of hand tremor.

摘要

本研究旨在回顾我们使用肉毒毒素 A(onaBoNT-A)治疗药物难治性手部震颤的长期经验。我们对 2010 年至 2018 年期间在至少 2 次就诊中接受 onaBoNT-A 治疗手部震颤并进行随访的患者数据库进行了回顾性分析。大多数患者在前臂屈肌(FF)注射(尽管治疗是个体化的)。在指定期间,91 名患者(53 名特发性震颤,31 名肌张力障碍性震颤,6 名帕金森病震颤和 1 名小脑传出震颤)符合我们的纳入标准。平均年龄(标准差)为 64.8 岁(12.8),平均随访时间为 29.6 个月(25.1),平均治疗次数为 7.7(6.3)次。89 名(97.8%)患者注射了 FF,74 名(81.3%)患者仅注射了 FF,15 名(16.5%)患者同时注射了 FF 和其他肌肉。5 名(5.5%)患者使用了肌电图引导。在 0⁻4“峰值效应”评分量表(0 = 无效应,4 = 严重度和功能显著改善)中,80.2%和 85.7%的患者在首次和末次随访时报告中度或显著改善(评分 3 或 4)。首次和末次随访的结果之间无统计学显著差异:平均“峰值效应”评分(3.2 与 3.4)、“总体”评分(3.0 与 3.2)、反应潜伏期(4.5 与 3.8 天)和总反应持续时间(12.7 与 12.8 周),但 onaBoNT-A 剂量除外(65.0 与 78.6 U/肢, = 0.002)。在 1095 次肢体注射中,有 134 次(12.2%)为非致残性和短暂性(平均 36 天)不良事件(132 次肢体无力,2 次疼痛)。onaBoNT-A 注射治疗手部震颤安全有效。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/b501/6070882/5f7a0f8867b6/toxins-10-00299-g001.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验